AMERSA

AMERSA

Call Us: (401) 615-4047 | Contact Us AMERSA on Twitter AMERSA on LinkedIn AMERSA on BlueSky

Make a Donation Join Our Mailing List
  • About
    • What is AMERSA
    • Board of Directors
    • Donate to AMERSA
    • Contact Us
  • Membership
    • Get to Know AMERSA
    • Join / Renew
    • Who We Are
    • Member Center
    • Special Interest Groups
    • Career Opportunities
    • Professional & Academic Advancement Opps
  • Conference
    • Annual Conference
    • Conference Sponsorship
    • Conference Exhibitor Information
    • Policy and Procedures for AMERSA Events
    • 2024 Conference Materials
    • Past Conference Resources
  • Journal
    • Journal Home
    • About Us
    • Member Access to Journal
    • Author Instructions and Submission
    • SAj Blog
    • SAj Annual Awards
    • SAj Editorial Scholar Program
  • Advocacy
    • AMERSA Advocacy
    • Position Statements
    • Submit a Position Statement
    • Letters of Support
    • Public Comments
  • Sustainability
    • Initiatives
    • Resources
  • Education
    • AMERSA Podcast Series
    • AMERSA Webinars
    • Core Competencies – AMERSA in the 21st Century
    • Resources
  • Awards
    • AMERSA Awards
    • Current Award Winners
    • Past Award Winners

Letters of Support

2025

AMERSA supports letter to HHS

AMERSA Public Comment re: Special Registrations for Telemedicine and Limited State Telemedicine Registrations

Reintroduction of Due Process of Continuity of Care Act

Drug Policy Alliance Amicus Brief Matter of L.B.

CPDD & Friends of NIDA Opposition to NIH Notice No. NOT-OD-25-068

2024

SUPPORT – AB 2115 (Haney) –Controlled Substances: Clinics

Letter to Kentucky Board of Medical Licensure – Review of 201 KAR 9:270 (buprenorphine regulation)

Call on 118th Congress to pass SUPPORT Act & MOTAA

Reentry Act and Due Process Continuity of Care Act Coalition Letter

2023

The Modernizing Opioid Treatment Access Act

Cosponsor of the Temporary Emergency Scheduling and Testing of Fentanyl Analogues Act of 2023

Expanding Telemedicine to Enhance Equity for Persons with Opioid Use Disorder: AMERSA Public Comment Responding to DEA Proposed Regulations for Buprenorphine Telehealth Regulations

AMERSA Public Comment re: Proposed Rulemaking 42 CFR Part 8 Medications for the Treatment of Opioid Use Disorder (RIN 0930-AA39)

Amicus Curiae Brief on Behalf of Medical and Public Health Organizations and Physicians and Midwives in Support of Defendant Kelsey Shande Carpenter

Reentry Act Endorsement

San Francisco Aids Foundation

Support for Patients and Communities Reauthorization Act (SUPPORT Act)

Temporary Emergency Scheduling and Testing of Fentanyl Analogues Act of 2023 (TEST Act)

2022

A Call for the FDA to Retract its Safety Communication Regarding Buprenorphine

2021

End the Fatal Paradox: Change the Names of our Federal Institutes on Addiction

Letter to State Officials: COVID and Harm Reduction

Letter in Opposition to Biden FRS Proposal

2020

AMERSA is concerned about the exponential harm caused by criminal justice actions pursued against persons who use drugs during pregnancy.  We are committed to supporting and advocating for the rights and protections of pregnant persons and their families.  AMERSA joined the Drug Policy Alliance in April 2020 and again in June 2020 in signing onto an urgent bail-related amicus brief in the case of The State of California v. Chelsea Cheyenne Becker, whose defense is being supported by National Advocates for Pregnant Women (NAPW). In October 2020, AMERSA again joined the Drug Policy Alliance in signing onto another bail-related amicus brief in the case of Audora Perez.

UPDATE: On March 9, 2021, Kings County Superior Court Judge Robert Shane Burns granted Chelsea Becker’s request to be released on her own recognizance so that she can enter a residential treatment facility, but her legal fight continues. Read the full statement.

  • DPA Amicus Letter Support Becker Petition Review Denial Writ Prohibition
  • DPA Amicus Letter Support Becker Petition for Review Habeas
  • 10.21.20 DPA Amicus Brief
  • 7.8.20 DPA Amicus Brief
  • 7.9.20 DPA Amicus Brief 2

Addressing Access to Care in the Opioid Epidemic and Preventing a Future Recurrence

  • Settlement Group Letter
  • White Paper

2019

AMERSA Opposes SUD Records Privacy Rule Change

Copyright © 2025
Site by: web360